Pharmacokinetic Study of Cytosine Arabinoside in Patients with Acute Myelogeneous Leukemia
The aim of the study was to evaluate the pharmacokinetics of cytosine arabinoside (Ara-C) and its extracellular metabolite uracil arabinoside Ara-U in patients with acute myelogeneous leukemia (AML) in correlation to response in therapy. There are few data  that indicate that high and long-lasting Ara-U plasma levels increase the incorportion of Ara-C into DNA and decrease the catabolism of Ara-C, and might also play a role in getting a response in therapy. We therefore investigated the pharmacokinetics of Ara-C and Ara-U in plasma of 17 patients with AML.
KeywordsAcute Myelogeneous Leukemia Kinetic Curf Cytosine Arabinoside Area Under Curve Uracil Arabinoside
Unable to display preview. Download preview PDF.
- 4.Capizzi RL, Yang JL, Cheng E, Cheng JC (1983) Pre-clinical and clinical pharmacology of high-dose Ara-C (HiDAC): aspects of “self potentiation” accounting for its unique therapeutic utility. In: 13th Int. Congress of Chemotherapy. Proceedings, Pt 216, pp 13–19Google Scholar
- 5.lacoboni S, Plunkett W, Keating M, McCredie K, Freireich E (1985) Pharmacologic direction of continuous infusion high dose Ara-C (CIHDAC) for refractory acute leukemia (RAL) and chronic myelogeneous leukemia blast crisis (CML-BC). American Society of Clinical Oncology 4:173, ASCO Abstr 674Google Scholar
- 7.Montgomery JA, Johnston TP, Thomas Hi, Piper JR, Temple Jr C (1979) The use of microparticular reversed-phase packing in high-pressure liquid chromatography of compounds of biological interest. Advan Chromatogr 15: 169–178Google Scholar
- 9.Plunkett W., Liliemark JO (1985) Evidence that accumulation of Ara-CTP by leukemic cells is saturated during high-dose Ara-C infusion: suggestions for increased efficiency of drug administration. American Society of Clinical Oncology 4:50, ASCO Abstr 192Google Scholar